Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more
Engineered AAV Capsid Production for Next-Generation Therapies
FREQUENTLY ASKED QUESTIONS
Engineered AAV Capsid Production for Next-Generation Gene Therapies
CELL & GENE | RNA | BIOLOGICS
Engineered AAV Capsid Production for Next-Generation Therapies
Executive Summary: Standard adeno-associated virus (AAV) serotypes can present limitations in tissue-specific delivery and may be neutralized by pre-existing antibodies in patient populations. Engineered AAV capsids are designed to overcome these barriers, offering tailored tissue tropism, enhanced transduction efficiency, and improved safety profiles by de-targeting non-target organs. Franklin Biolabs, launched in 2024, combines the historical expertise of the core scientific leadership from the former Penn Vector Core within a >100,000 sq ft GxP-ready facility to produce these novel and refractory capsids, accelerating programs toward IND submission.
How do engineered AAV capsids impact IND-enabling toxicology studies?
Engineered AAV capsids directly influence the design of IND-enabling toxicology studies by altering the vector’s biodistribution and potential immunogenicity. A capsid designed for specific tropism, such as CNS penetration, requires a toxicology program that meticulously evaluates that target tissue while confirming minimal expression in non-target tissues. This focused approach can yield a cleaner safety profile, a foundational component of a successful IND submission.
What factors influence the production timeline for a novel or refractory AAV capsid?
The production timeline for a novel or refractory AAV capsid is influenced by several factors. These include custom design considerations, potential optimization of transfection and packaging protocols, and the development of specific QC analytics required to characterize the unique vector. Each of these steps is managed to align with the program’s overall preclinical schedule.
Can Franklin Biolabs’ vector production support multi-jurisdictional submissions, including to the MHRA or under ICH guidelines?
Yes. Our analytical and manufacturing processes are built to support global regulatory filings. The data packages generated for our research and preclinical vectors are designed with multi-jurisdictional submissions in mind, aligning with harmonized international guidelines (ICH) to facilitate concurrent IND and IMPD applications for sponsors targeting both US and European clinical trials.
Moving Beyond Off-the-Shelf AAV Serotypes
The therapeutic potential of a gene therapy is fundamentally linked to the delivery efficiency and specificity of its AAV vector. While naturally occurring serotypes have enabled significant clinical progress, many next-generation therapies require vectors with rationally designed capsids to achieve superior performance. These engineered capsids are developed to solve specific biological challenges.
Key objectives for capsid engineering include:
-
Altering Tissue Tropism: Directing the vector to specific cell populations (e.g., neurons, muscle cells) while de-targeting others, such as the liver, to minimize potential toxicity.
-
Evading Neutralizing Antibodies (NAbs): Modifying surface-exposed epitopes to bypass pre-existing immunity, thereby expanding the eligible patient population.
-
Enhancing Transduction Efficiency: Increasing the vector’s ability to enter target cells and deliver its genetic payload, potentially allowing for lower, safer doses.
The scientific team at Franklin Biolabs, formally launched in 2024, includes the core leadership from the former Penn Vector Core. This continuity ensures that programs benefit from decades of hands-on experience in producing these complex vectors.
“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption… Franklin Biolabs is our core manufacturing collaborator for our AAV-vector based gene therapy candidate development, and we look forward to continuing this productive relationship.”
– Biotech Partner
Designing Vectors with a Clear Translational Endpoint
The selection or engineering of a capsid is a strategic decision with direct implications for the entire preclinical program, a primary factor in achieving an 18-24 month timeline to IND. For instance, preclinical data shows that specific AAV delivery approaches can induce immunological tolerance, a finding that has significant implications for managing host immune responses in the clinic (PMID: 26022732).
Similarly, using an optimized vector to correct a deficiency early can prevent the downstream cascade of chronic tissue damage, demonstrating the long-term value of precise, upfront vector engineering (PMID: 28283349). Our approach to vector production is informed by this translational mindset. We focus on creating vectors that are not only high-quality but also strategically aligned with the sponsor’s clinical and regulatory goals. For a deeper look into these strategic considerations, our recent webinar covers the key factors for initiating successful AAV programs.
This focus on manufacturability and clinical viability is central to our work, including our leading industry partners to develop next-generation in vivo gene editing therapies. By producing vectors with defined characteristics, we provide the foundational tools needed for robust preclinical evaluation and transition into GxP manufacturing.
For programs utilizing established serotypes, please see our primary AAV Research Vector Packaging Services page.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.